Sample Collection Study for Scientific Evaluation of Laboratory Interference of CyFlow™ Antibodies for Flow Cytometry
Conditions
Interventions
Group 1: In vitro evaluation of antibody products.
No special examinations are carried out as part of the study. Blood samples are taken as part of the routine examination of diabetes patients.
Sponsors
PSHI Praxis GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Patients who are subject to a medically indicated venous blood draw in the course of daily routine practice. • Subjects who agree to the drawing of an additional 9 mL blood sample through the venous line in place that will be used for laboratory tests.
Exclusion criteria
Exclusion criteria: • Lack of compliance or other justifications that precludes satisfactory participation in the study in the opinion of the Investigator. • Inability to understand the nature and the extent of the study and the procedures required. • Participation without legal capacity • Pregnant and nursing women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Collection of venous blood samples for in-vitro Interference tests for CyFlow™ antibody products. Venous blood draw of 9 ml EDTA whole blood during visit 1. The study has no regular primary endpoint. The aim of the study is the determination of interference of the CyFlow™ antibody products in the laboratory. | — |
Countries
Germany
Contacts
Public ContactAndreas Pfützner
PSHI Praxis GmbH
Outcome results
None listed